Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 4
Submit an article Journal homepage
438
Views
0
CrossRef citations to date
0
Altmetric
Review

Beyond the Clinic: ‘Direct-to-Consumer‘ Genomic Profiling Services and Pharmacogenomics

Barbara Prainsack1 Department of Social Science, Health & Medicine, King‘s College London,Strand, LondonWC2R 2LS, UK. [email protected]
&
Effy Vayena2 Institute of Biomedical Ethics, University of Zurich, Pestalozzistrasse 24, 8032Zurich, Switzerland
Pages 403-412 | Published online: 25 Feb 2013

References

  • Topol E . The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care. Basic Books, NY, USA (2012).
  • Wright C , MacArthurDG. Direct to consumer genetic testing. In: Molecular Genetics and Personalized Medicine – Molecular and Translational Medicine. Best DH, Swensen JJ (Eds). Springer, NY, USA (2012).
  • Imai K , KrickaLJ, FortinaP. Concordance study of 3 direct-to-consumer genetic-testing services. Clin. Chem.57 , 518–521 (2011).
  • Zehnbauer B . Direct-to-consumer genetics testing – fair comparisons? Clin. Chem.57 , 369–371 (2011).
  • Eriksson N , MacphersonJM, TungJY et al. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 6 , e1000993 (2010).
  • Do CB , TungJY, DorfmanE et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson‘s disease. PLoS Genet. 7(6) , e1002141 (2011).
  • Tung JY , DoCB, HindsDA et al. Efficient replication of over 180 genetic associations with self-reported medical data. PLoS ONE 6(8) , e23473 (2011).
  • Howard HC , BorryP. Direct-to-consumer genetic testing: More questions than benefits? Per. Med.5(4) , 317–320 (2008).
  • Feero WG , GuttmacherAE, CollinsFS. The genome gets personal – almost. JAMA299 , 1351–1352 (2008).
  • Hunter DJ , KhouryMJ, DrazenJM. Letting the genome out of the bottle – will we get our wish? N. Engl. J. Med.358(2) , 105–107 (2008).
  • Kraft P , HunterDJ. Genetic risk prediction – are we there yet? N. Engl. J. Med.360(17) , 1701–1703 (2009).
  • Caulfield T , McGuireAL. Direct-to-consumer genetic testing: perceptions, problems, and policy responses. Annu. Rev. Med.63 , 23–33 (2012).
  • Khoury MJ , BergA, CoatesR et al. The evidence dilemma in genomic medicine. Health Aff. (Millwood) 27(6) , 1600–1611 (2009).
  • Caulfield T . Direct-to-consumer genetics and health policy? A worst-case scenario? Am. J. Bioeth.9(6) , 48–50 (2009).
  • James KM , CowlCT, TilburtJC et al. Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. Mayo Clin. Proc. 86(10) , 933–940 (2011).
  • Nordgren A . Neither as harmful as feared by critics nor as empowering as promised by providers: risk information offered direct to consumer by personal genomics companies. J. Community Genet. doi:10.1007/s12687–012–0094–0090) (2012) (Epub ahead of print).
  • Howard H , BorryP. Direct-to-consumer pharmacogenomic testing. Pharmacogenomics12(10) , 1367–1370 (2011).
  • Leighton JW . The general public‘s understanding and perception of DTC genetic test results. Public Health Genomics15 , 11–21 (2012).
  • Vayena E , MauchF.Personal genomics: are we debating the right issues? Praxis (Bern 1994)101(15) , 961–964 (2012).
  • Hudson K , JavittG, BurkeW, Byers P; ASHG Social Issues Committee. ASHG statement* on direct-to-consumer genetic testing in the United States. Am. J. Hum. Genet.81(3) , 635–637 (2007).
  • European Society of Human Genetics (ESHG). Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur. J. Hum. Genet.12 , 1271–1273 (2010).
  • Committee on Genetics, American College of Obstetricians and Gynecologists; Committee on Ethics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 409: direct-to-consumer marketing of genetic testing. Obstet. Gynecol.111(6) , 1493–1494 (2008).
  • Foster MW , MulvihillJJ, SharpRR. Evaluating the utility of personal genomic information. Genet. Med.11(8) , 570–574 (2009).
  • Myers MF . Health care providers and DTC access and advertising of genetic testing in the US. Genome Med.3(12) , 81 (2011).
  • Udesky L . The ethics of direct-to-consumer genetic testing. Lancet376(9750) , 1377–1378 (2010).
  • Colaiacovo M , GrimaldiKA. Personal genetics, the European regulations maze and the way out. Per. Med.9(5) , 515–522 (2012).
  • Borry P , van Hellemondt RE, Sprumont D et al. Legislation on direct-to-consumer genetic testing in seven European countries. Eur. J. Hum. Genet.20(7) , 715–721 (2012).
  • Soini S . Genetic testing legislation in western Europe – a fluctuating regulatory target. J. Community Genet.3(2) , 143–153 (2012).
  • Lee SS , CrawleyL. Research 2.0: social networking and direct-to-consumer (DTC) genomics. Am. J. Bioeth.9(6) , 35–44 (2009).
  • Juengst ET , Flatt,MA, SetterstenRA Jr. Personalized genomic medicine and the rhetoric of empowerment. Hastings Cent. Rep.35 , 34–40 (2012).
  • Howard HC , BorryP. Is there a doctor in the house? The presence of physicians in the direct-to-consumer genetic testing context. J. Community Genet.3(2) , 105–112 (2012).
  • Evans JP , BergJS. Next-generation DNA sequencing, regulation, and the limits of paternalism: the next challenge. JAMA306(21) , 2376–2377 (2011).
  • Howard HC , BorryP. To ban or not to ban? Clinical geneticists‘ views on the regulation of direct-to-consumer genetic testing. EMBO Rep.13(9) , 791–794 (2012).
  • McBride CM , WadeCH, KaphingstKA. Consumers‘ views of direct-to-consumer genetic information. Annu. Rev. Genomics Hum. Genet.11 , 427–446 (2010).
  • McGowan ML , FishmanJR, LambrixMA. Personal genomics and individual identities: Motivations and moral imperatives of early users. New Genet. Soc.29(3) , 261–290 (2010).
  • Vayena E , GournaE, StreuliJ, HafenE, PrainsackB. Early users of direct-to-consumer genomics in Switzerland. Public Health Genomics15(6) , 352–362 (2012).
  • Chua EW , KennedyMA. Current state and future prospects of direct-to-consumer pharmacogenetics. Front. Pharmacol.3 , 152 (2012).
  • Kitzmiller JP , GroenDK, PhelpsMA, SadeeW. Pharmacogenomics testing: relevance in medical practice. Cleve. Clin. J. Med.78(4) , 243–257 (2011).
  • Gurwitz D , Bregman-EschetY. Personal genomics services: whose genomes? Eur. J. Hum. Genet.17(7) , 883–889 (2009).
  • Rose N . The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton University Press, NJ, USA (2008).
  • Prainsack B , ReardonJ, HindmarshR, GottweisH, NaueU, LunshofJE. Misdirected precaution? Nature456 , 34–35 (2008).
  • Gurwitz D , LunshofJE. Personalized participatory medicine: sharing knowledge and uncertainty. Genome Med.3(10) , 69 (2011).
  • Wysowski DK , NourjahP, SwartzL. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med.167 , 1414–1419 (2007).
  • Budnitz DS , PollockDA, WeidenbachKN, MendelsohnAB, SchroederTJ, AnnestJL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA296 , 1858–1866 (2007).
  • Kim MM , MetlayJ, CohenA et al. Hospitalization costs associated with warfarin- related bleeding events among older community-dwelling adults. Pharmacoepidemiol. Drug Saf. 19 , 731–736 (2010).
  • Frueh F . On rat poison and human medicines: personalizing warfarin therapy. Trends Mol. Med.18(4) , 201–205 (2012).
  • Cohen JP . Overcoming regulatory and economic challenges facing pharmacogenomics. New Biotechnology29(6) , 751–756 (2012).
  • Harper AR , TopolEJ. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol.30(11) , 1117–1124 (2012).
  • Flanigan J . Three arguments against prescription requirements. J. Med. Ethics38(10) , 579–586 (2012).
  • Higgs JE , AndrewsJ, GurwitzD, PayneK, NewmanW. Pharmacogenetics education in british medical schools. Genomic Med.2(3–4) , 101–105 (2008).
  • Gurwitz D . Pharmacogenetics education: 10 years of experience at Tel Aviv University. Pharmacogenomics11(5) , 647–649 (2010).
  • Dias MM , DepalaK, WardHM et al. Reforming pharmaceutical education to enhance the global uptake of pharmacogenomics and personalized medicine. Curr. Pharmacogenomics Person. Med. 10(3) , 231–238 (2012).
  • Lunshof JE , GurwitzD. Pharmacogenomic testing: Knowing more, doing better. Clin. Pharmacol. Ther.91(3) , 387–389 (2012).
  • Stanek EJ , SandersCL, TaberKA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3) , 450–458 (2012).
  • Haga S , BurkeW, GinsburgG, MillsR, AgansR. Primary care physicians‘ knowledge and experience with pharmacogenomics testing. Clin. Genet.82(4) , 388–394 (2012).
  • Haga SB , O‘DanielJMO, TindallGM, LipkusIR, AgansR. Survey of US public attitudes towards pharmacogenetic testing. Pharmacogenomics J.12 , 197–105 (2011).
  • Mesko B , ZahuczkyG, NagyL. The triad success in personalised medicine: pharmacogenomics, biotechnology and regulatory issues from a central European perspective. Nat. Biotechnol.29(6) , 741–750 (2012).
  • Paré G , MehtaSR, YusufS et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18) , 1704–1714 (2010).
  • Mega JL , SimonT, ColleetJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 304(16) , 1821–1830 (2010).
  • Simon T , VerstuyftC, Mary-KrauseM. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4) , 363–375.
  • Mega JL , CloseSL, WiviottSD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).

▪Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.